Foresite Capital ACRS Position
Exited6-Fund ConvergenceForesite Capital exited their position in Aclaris Therapeutics Inc. (ACRS) in Q4 2023, after holding the stock for 4 quarters.
The position was first reported in Q1 2023 and has been tracked across 4 quarterly 13F filings.
ACRS is a convergence signal: 6 specialist biotech funds hold this stock, suggesting high institutional conviction.
There is an upcoming Phase 2 readout for ATI-045 in 137 days (Aug 31, 2026), making the timing of Foresite's position particularly relevant.
About Aclaris Therapeutics Inc.
Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment engages in the provision of laboratory services. The company also develops Zunsemetinib, an MK2 inhibitor for the treatment of moderate to severe rheumatoid and Psoriatic arthritis, and Hidradenitis suppurativa; and ATI-1777, a soft JAK 1/3 inhibitor for the treatment of moderate to severe atopic dermatitis. In addition, it develops ATI-2138, an ITK/TXK/JAK3 inhibitor as a potential treatment for T cell-mediated autoimmune diseases; Gut-Biased Program for inflammatory bowel disease; and ATI-2231, an MK2 inhibitor treatment for pancreatic and metastatic breast cancer. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.
Full company profile →Short Interest
4.5%
1.8 days to cover
Foresite Capital ACRS Position History
Frequently Asked Questions
Does Foresite Capital own ACRS?
No. Foresite Capital exited their position in Aclaris Therapeutics Inc. (ACRS) in Q4 2023. They previously held the stock for 4 quarters.
How many hedge funds own ACRS?
6 specialist biotech hedge funds currently hold ACRS, including BVF Partners, RA Capital Management, Rock Springs Capital and 3 more. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Foresite Capital first buy ACRS?
Foresite Capital's position in ACRS was first reported in Q1 2023. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Foresite Capital's ACRS position increasing or decreasing?
Foresite Capital completely exited their ACRS position in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
ACRSCompany Page →
All fund holders, insider trades, catalysts, and cash runway
Foresite CapitalPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →